Skip to main content
. 2011 Sep;20(121):201–207. doi: 10.1183/09059180.00002011

Figure 2.

Figure 2.

Effects of pirfenidone on vital capacity (VC) at week 52 in a Japanese phase III trial. The last observation carried forward method was used for drop-outs in each group. Data are presented as mean±se. Placebo group: n = 103; high-dose group: n = 104; low-dose group: n = 54. #: p<0.1, comparison of adjusted means based on ANCOVA (negative and positive of the changes represent deterioration and improvement from baseline, respectively). Reproduced from [31].